0.00
price down icon100.00%   -9.71
 
loading
前日終値:
$9.71
開ける:
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額:
$39.28M
収益:
$147.75M
当期純損益:
$-284.23M
株価収益率:
0.00
EPS:
-2.93
ネットキャッシュフロー:
$-317.54M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
Value
$0.00
$0.00
1週間の範囲:
Value
$0.00
$0.00
52週間の値動き範囲:
Value
$0.00
$21.94

Fibrogen Inc Stock (FGEN) Company Profile

Name
名前
Fibrogen Inc
Name
セクター
Healthcare (1111)
Name
電話
415-978-1200
Name
住所
350 BAY STREET, SAN FRANCISCO, CA
Name
職員
225
Name
Twitter
@FibroGenInc
Name
次回の収益日
2025-03-17
Name
最新のSEC提出書
Name
FGEN's Discussions on Twitter

FGEN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FGEN
Fibrogen Inc
0.00 39.28M 147.75M -284.23M -317.54M -2.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.90 120.69B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
741.45 78.77B 14.34B 4.50B 3.88B 41.57
Biotechnology icon
ARGX
Argen X Se Adr
840.50 52.46B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
338.06 45.82B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
340.38 38.73B 4.98B 69.59M 525.67M 0.5197

Fibrogen Inc Stock (FGEN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-08-08 ダウングレード BofA Securities Neutral → Underperform
2023-06-26 ダウングレード BofA Securities Buy → Neutral
2023-06-26 ダウングレード Raymond James Outperform → Mkt Perform
2023-06-26 ダウングレード Stifel Buy → Hold
2023-06-26 ダウングレード William Blair Outperform → Mkt Perform
2023-06-02 アップグレード Stifel Hold → Buy
2023-01-31 アップグレード William Blair Mkt Perform → Outperform
2023-01-26 アップグレード Raymond James Mkt Perform → Outperform
2023-01-05 アップグレード BofA Securities Neutral → Buy
2021-09-22 ダウングレード Goldman Neutral → Sell
2021-08-20 アップグレード Raymond James Underperform → Mkt Perform
2021-07-16 ダウングレード BofA Securities Buy → Neutral
2021-07-16 ダウングレード Stifel Buy → Hold
2021-04-07 ダウングレード H.C. Wainwright Buy → Neutral
2021-04-07 ダウングレード Mizuho Buy → Neutral
2021-03-31 アップグレード BofA Securities Neutral → Buy
2021-03-02 ダウングレード Jefferies Buy → Hold
2021-02-01 開始されました H.C. Wainwright Buy
2020-10-26 開始されました Raymond James Underperform
2020-07-10 再開されました Stifel Buy
2020-05-01 開始されました Cowen Market Perform
2020-04-27 開始されました BofA/Merrill Neutral
2019-05-29 再開されました Goldman Neutral
2019-05-10 ダウングレード William Blair Outperform → Mkt Perform
2019-04-12 開始されました Piper Jaffray Neutral
2019-02-11 再開されました Stifel Buy
2018-12-19 アップグレード Citigroup Neutral → Buy
2017-08-08 繰り返されました Leerink Partners Outperform
2017-08-08 繰り返されました Stifel Buy
2017-07-21 ダウングレード Goldman Buy → Neutral
2017-07-11 開始されました Jefferies Buy
2016-02-11 アップグレード Credit Suisse Neutral → Outperform
2016-01-21 開始されました Credit Suisse Neutral
2015-12-04 開始されました Citigroup Buy
2015-09-23 開始されました Lake Street Hold
2015-07-29 開始されました Citigroup Buy
2015-07-20 アップグレード Goldman Neutral → Buy
2014-12-09 開始されました Stifel Buy
すべてを表示

Fibrogen Inc (FGEN) 最新ニュース

pulisher
Jan 29, 2026

Aug Movers: Will FibroGen Inc benefit from AI trends2025 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn

Jan 29, 2026
pulisher
Jan 25, 2026

Sentiment Review: Will FibroGen Inc benefit from AI trendsWeekly Market Report & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn

Jan 25, 2026
pulisher
Jan 24, 2026

Quarterly Risk: Will FibroGen Inc benefit from AI trends2025 Retail Activity & Smart Allocation Stock Tips - baoquankhu1.vn

Jan 24, 2026
pulisher
Jan 18, 2026

Price Action: Can FibroGen Inc be the next market leader2025 Trading Volume Trends & Fast Gain Swing Alerts - baoquankhu1.vn

Jan 18, 2026
pulisher
Jan 14, 2026

Aug Technicals: Will FibroGen Inc stock benefit from M AWeekly Market Outlook & Community Trade Idea Sharing - baoquankhu1.vn

Jan 14, 2026
pulisher
Jan 13, 2026

Jobs Data: Will FibroGen Inc. stock outperform international peers2025 Winners & Losers & Safe Capital Growth Tips - Bộ Nội Vụ

Jan 13, 2026
pulisher
Jan 13, 2026

Sentiment Review: Will FibroGen Inc benefit from government policyMarket Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn

Jan 13, 2026
pulisher
Jan 13, 2026

Aug Sentiment: Is FibroGen Inc. stock heavily shorted2025 Market Outlook & Weekly Watchlist of Top Performers - baoquankhu1.vn

Jan 13, 2026
pulisher
Jan 13, 2026

RSI Check: Why FibroGen Inc stock remains on buy listsShort Setup & Reliable Intraday Trade Alerts - Bộ Nội Vụ

Jan 13, 2026
pulisher
Jan 10, 2026

How FibroGen Inc. stock reacts to inflationary pressuresJuly 2025 Drop Watch & Risk Managed Investment Signals - Улправда

Jan 10, 2026
pulisher
Jan 08, 2026

Trend Recap: Why FibroGen Inc. stock is a must watch in 2025Trade Signal Summary & Technical Confirmation Trade Alerts - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Why FibroGen Inc. stock is a must watch in 2025Market Growth Report & Fast Exit and Entry Trade Guides - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Aug Chart Watch: Is FibroGen Inc. stock undervalued vs historical averagesJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Published on: 2026-01-09 00:07:25 - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Is FibroGen Inc. stock a buy before product launches2025 Trading Recap & AI Based Trade Execution Alerts - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - MarketScreener

Jan 08, 2026
pulisher
Jan 08, 2026

FibroGen (FGEN) Faces Option Delistings as of January 8th - GuruFocus

Jan 08, 2026
pulisher
Jan 08, 2026

One new option listing and one option delisting on January 8th - TipRanks

Jan 08, 2026
pulisher
Jan 08, 2026

FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB By Investing.com - Investing.com Nigeria

Jan 08, 2026
pulisher
Jan 08, 2026

FibroGen nabs ex-Lilly Conterno as CEO - The Pharma Letter

Jan 08, 2026
pulisher
Jan 07, 2026

FibroGen (FGEN) Transforms into Kyntra Bio with a New Focus - GuruFocus

Jan 07, 2026
pulisher
Jan 07, 2026

FibroGen stock rises after announcing rebrand to Kyntra Bio By Investing.com - Investing.com South Africa

Jan 07, 2026
pulisher
Jan 07, 2026

FibroGen stock rises after announcing rebrand to Kyntra Bio - Investing.com

Jan 07, 2026
pulisher
Jan 07, 2026

FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB - Investing.com

Jan 07, 2026
pulisher
Jan 07, 2026

FibroGen, Inc. Rebrands to Kyntra Bio, Targeting Oncology and Rare Disease Therapeutics with New Nasdaq Trading Symbol "KYNB" - Quiver Quantitative

Jan 07, 2026
pulisher
Jan 07, 2026

FibroGen rebrands to Kyntra Bio - marketscreener.com

Jan 07, 2026
pulisher
Dec 28, 2025

Quarterly Earnings: Is FibroGen Inc stock a buy before product launchesJuly 2025 Review & Weekly Momentum Picks - moha.gov.vn

Dec 28, 2025
pulisher
Dec 23, 2025

FibroGen shares advance after roxadustat earns orphan drug status - MSN

Dec 23, 2025
pulisher
Dec 20, 2025

Published on: 2025-12-20 23:42:14 - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Why FibroGen Inc. (1FG0) stock attracts HNW investorsRecession Risk & Reliable Breakout Stock Forecasts - Улправда

Dec 20, 2025
pulisher
Dec 19, 2025

FibroGen Q3 2025 Earnings Preview - MSN

Dec 19, 2025
pulisher
Dec 19, 2025

Published on: 2025-12-19 15:46:05 - Улправда

Dec 19, 2025
pulisher
Dec 18, 2025

Will FibroGen Inc. stock outperform international peers2025 Market Trends & Safe Capital Preservation Plans - Улправда

Dec 18, 2025
pulisher
Dec 18, 2025

Published on: 2025-12-18 12:26:14 - Улправда

Dec 18, 2025
pulisher
Dec 16, 2025

Is FibroGen (NASDAQ:FGEN) A Risky Investment? - simplywall.st

Dec 16, 2025
pulisher
Dec 15, 2025

FDA grants orphan drug designation to FibroGen’s roxadustat for MDS By Investing.com - Investing.com Nigeria

Dec 15, 2025
pulisher
Dec 15, 2025

FDA grants orphan drug designation to FibroGen’s roxadustat for MDS - Investing.com India

Dec 15, 2025
pulisher
Dec 15, 2025

FibroGen stock rises after roxadustat receives Orphan Drug Designation By Investing.com - Investing.com Nigeria

Dec 15, 2025
pulisher
Dec 15, 2025

FibroGen stock rises after roxadustat receives Orphan Drug Designation - Investing.com India

Dec 15, 2025

Fibrogen Inc (FGEN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Fibrogen Inc (FGEN) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Wettig Thane
CEO
Nov 13 '25
Buy
9.18
1,000
9,180
22,239
Schoeneck James A
Director
Jun 30 '25
Buy
5.07
23,567
119,485
39,666
Wettig Thane
CEO
Mar 24 '25
Buy
0.35
145,000
50,663
543,329
Schoeneck James A
Director
Mar 20 '25
Buy
0.35
250,000
88,000
323,722
Schoeneck James A
Director
Mar 21 '25
Buy
0.34
50,000
17,040
373,722
$96.95
price down icon 1.27%
$100.07
price down icon 1.00%
$32.63
price down icon 2.16%
$113.75
price down icon 2.59%
$156.87
price down icon 0.60%
biotechnology ONC
$340.38
price down icon 2.75%
大文字化:     |  ボリューム (24 時間):